54.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$54.99
Aprire:
$53.15
Volume 24 ore:
764.86K
Relative Volume:
0.89
Capitalizzazione di mercato:
$3.36B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
20.68
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
-4.33%
1M Prestazione:
+1.56%
6M Prestazione:
+43.36%
1 anno Prestazione:
+41.67%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PTGX
Protagonist Therapeutics Inc
|
54.19 | 3.41B | 45.48M | 169.95M | 230.85M | 2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-17 | Iniziato | Citigroup | Buy |
2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
2024-12-06 | Iniziato | Goldman | Neutral |
2024-11-05 | Iniziato | Wedbush | Outperform |
2024-09-24 | Iniziato | TD Cowen | Buy |
2024-09-09 | Iniziato | Truist | Buy |
2023-10-30 | Iniziato | CapitalOne | Overweight |
2023-05-25 | Ripresa | Jefferies | Buy |
2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
2022-02-11 | Iniziato | BTIG Research | Buy |
2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
2021-05-24 | Iniziato | Northland Capital | Outperform |
2021-01-06 | Iniziato | JP Morgan | Overweight |
2020-12-16 | Iniziato | Piper Sandler | Overweight |
2020-09-18 | Reiterato | H.C. Wainwright | Buy |
2020-07-15 | Iniziato | Jefferies | Buy |
2020-05-18 | Reiterato | H.C. Wainwright | Buy |
2019-07-08 | Iniziato | H.C. Wainwright | Buy |
2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
2018-12-06 | Iniziato | Nomura | Buy |
2018-01-29 | Iniziato | Stifel | Buy |
2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com India
Protagonist Therapeutics Inc. Stock Analysis and ForecastRapid-fire capital growth - jammulinksnews.com
What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional
Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com
What analysts say about Protagonist Therapeutics Inc. stockConsistent triple returns - jammulinksnews.com
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal
Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Lancaster Eagle-Gazette
Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus
How the (PTGX) price action is used to our Advantage - news.stocktradersdaily.com
How Protagonist Therapeutics Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser
Why Protagonist Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
What makes Protagonist Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser
Insiders At Protagonist Therapeutics Sold US$5.1m In Stock, Alluding To Potential Weakness - 富途牛牛
Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity - BioWorld MedTech
Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist - insights.citeline.com
Transcript : Protagonist Therapeutics, Inc.Special Call - MarketScreener
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - The Oklahoman
Protagonist Therapeutics to Host Conference Call to Announce an - GuruFocus
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Yahoo Finance
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Yahoo Finance
10 Biotech Stocks Screaming a Buy - Insider Monkey
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus
Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):